Evaluation of antimicrobial treatments in children with acute otitis media in Spain: A pharmacokinetic-pharmacodynamic (PK/PD) approach

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 628-635

  Beobide, I ^a   Canut, A ^a   Gascon A R ^b   Isla, A ^b   Garcia Rey C ^c   De La Maza, I ^a   Labora, A ^a   Pedraz, José Luis ^b  

^a HOSPITAL TXAGORRITXU   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

Acute otitis media; Antibiotics; Children; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE;

ACUTE OTITIS MEDIA; ARTICLE; BACTERICIDAL ACTIVITY; CHILDHOOD DISEASE; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 30744460119     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.628     Document Type: Article

References (48)

1. Solis G, Ochoa C, Perez Mendez C. The variability and appropriateness of the antibiotic prescription of acute otitis media in childhood. The Spanish Study Group for Antibiotic Treatments. Int J Pediatr Otorhinolaryngol 2000; 56:175-84.
2. del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998; 17:94-7.
3. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 Suppl 3:38-44.
4. Canafax DM, Yuan Z, Chonmaitree T, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J 1998; 17:149-56.
5. Thoroddsen E, Marr C, Efthymiopoulos C, Thorarinsson H. Concentration of cefuroxime in middle ear effusion of children with acute otitis media. Pediatr Infect Dis J 1997; 16, 959-962.
6. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J 1998; 17:258-60.
7. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15:255-9.
8. Harrison CJ. Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy. Pediatr Infect Dis J 1997; 16:512-6.
9. Blumer JL. Fundamental basis for rational therapeutics in acute otitis media. Pediatr Infect Dis J 1999; 18:1130-40.
10. Scaglione F, Caronzolo D, Pintucci JP, Fraschini F. Measurement of cefaclor and amoxicillin-clavulanic acid levels in middle-ear fluid in patients with acute otitis media. Antimicrob Agents Chemother 2003; 47:2987-9.
11. Sundberg L, Eden T. Penetration of enoxacin into middle ear effusion. Acta Otolaryngol 1990; 109:438-43.
12. Eden T. Long-standing otitis media with effusion - a convenient model for the study of antibiotic penetration to respiratory tract secretions. Scand J Infect Dis Suppl 1985; 44:46-51.
13. Shyu WC, Haddad J, Reilly J, et al. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994; 38:2210-2.
14. Isla A, Canut A, Gascón AR, et al. Pharmacokinetic/ pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections. Clin Pharmacokinet 2005; 44:305-16.
15. Schaad UB, Casey PA, Ravenscroft AT. Pharmacokinetics of a syrup formulation of amoxycillin-potassium clavulanate in children. J Antimicrob Chemother 1986; 17:341-5.
16. Ginsburg CM, McCracken GH, Jr., Thomas ML, Clahsen J. Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children. Pediatrics 1979; 64:627-31.
17. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 2001; 61:1455-500.
18. Taylor CJ, Johnson TN. Cefuroxime axetil pediatric suspension: a pharmacokinetic evaluation. Research Clin Forums 1990; 12:31-36.
19. Rocephin. (ceftriaxone) package insert. Nutley, New Jersey: Roche Pharmaceuticals, 2000.
20. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, Bouza E, Aguilar L, Garcia-de-Lomas J, Baquero F; Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334-40.
21. Marco F, Garcia-de-Lomas J, Garcia-Rey C, Bouza E, Aguilar L, Fernandez-Mazarrasa C. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001; 45:3226-8.
22. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52:229-46.
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edition. Approved standard M7-A6. NCCLS, Wayne, Pa. USA., 2003.
24. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 (Suppl 1): S13-20.
25. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:35-40.
26. Bowker KE, Noel AR, MacGowan AP. The magnitude of the pharmacodynamic index which determines outcome with amoxicillin/clavulanate is similar for Streptococcus pneumoniae and Haemophilus influenzae and not dependant on inoculum., 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Vol. Abstract A1158.
27. Craig WA. Antimicrobial resistance issues of the future. Diag Microbiol Infect Dis 1996; 25, 213-217.
28. Perez-Trallero E, Marimon JM, Gonzalez A, Garcia-Rey C, Aguilar L. Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2003; 47:3637-9.
29. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 Suppl 1:i3-20.
30. Casal J, Gimenez MJ, Aguilar L, et al. Beta-lactam activity against resistant pneumococcal strains is enhanced by the immune system. J Antimicrob Chemother 2002: 50 (Suppl S2): 83-6.
31. Aguilar L, Gimenez MJ, Garcia-Rey C, Martin JE. New strategies to overcome antimicrobial resistance in Streptococcus pneumoniae with beta-lactam antibiotics. J Antimicrob Chemother 2002; 50 (Suppl S2):93-100.
32. Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:1040-5.
33. Dagan R. Treatment of acute otitis media - challenges in the era of antibiotic resistance. Vaccine 2000; 19 (Suppl 1): S9-S16.
34. Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95-104.
35. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20:829-37.
36. Scaglione F. Predicting the clinical efficacy of antibiotics: toward definitive criteria. Curr Therapeutic Res 1997; 16 (Suppl.3): 56-59.
37. Sundberg L, Cederberg A. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media. J Antimicrob Chemother 1994; 33, 299-307.
38. Gan VN, Chu SY, Kusmiesz H, Craft JC. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992; 36: 2478-2480.
39. Guay DRP, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993; 12, 106-111.
40. www.fda.gov/ohrms/dockets/ac/01/briefing/ 3802b1_01_pfizer.pdf
41. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996; 37, (Suppl. C): 53-61.
42. Dagan R, Leibovitz E, Fliss DM, Leiberman I, Jacobs MR, Craig W, Yagupsky P. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44, 43-50.
43. Rothermel CD. Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale. Curr Ther Res 2003; 65:4-15.
44. Arguedas A, Loaiza C, Perez A, Gutierrez A, Herrera ML, Rothermel CD. A pilot study of single-dose azithromycin versus three-day azithromycin or single-dose ceftriaxone for uncomplicated acute otitis media in children. Curr Ther Res 2003; 64:A16-A29.
45. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother 2003; 47:3179-86.
46. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002; 50 (Suppl S2):87-92.
47. World Health Organization. WHO report on infectious diseases. Overcoming antimicrobial resistance. WHO, Geneva, Switzerland, 2000.
48. World Health Organization. WHO model prescribing information, drugs used in bacterial infections. WHO, Geneva, Switzerland, 2001.